Gland Pharma Limited (GLAND) — Corporate Action

📢 Key Event
Gland Pharma declared a final dividend of ₹20 per share for FY25-26, with record date on August 11, 2026 and AGM on August 25, 2026.

🔄 What Changed
Net profit after tax of ₹13,720.62 million; 14.5% YoY revenue growth to ₹10,273.16 million; 22% Q4 revenue growth; 36% YoY CDMO revenue growth; ₹20 dividend recommendation.

🔮 What's Next
Fontenay facility expansion to add 30 million ampoule capacity by 2027; new oncology CDMO contract secured; pipeline includes six launched complex products and three pending approvals.

💡 Investor Takeaway
The ₹20 dividend and strong growth in CDMO and international markets signal robust financial health and shareholder-friendly returns.

Gland Pharma announced a final dividend of ₹20 per share (2000% on ₹1 face value) for FY25-26, with record date on August 11, 2026, and AGM scheduled for August 25, 2026. The Board approved audited consolidated financial results showing ₹13,720.62 million net profit after tax, ₹20 recommended dividend, and unmodified auditor opinion. Revenue reached ₹10,273.16 million for the year, with 14.5% YoY growth in FY26 driven by 22% Q4 growth. CDMO segment contributed 46% of revenue, growing 36% YoY in Q4. The company filed 8,388 ANDAs and approved 11,337, with six complex products launched and three pending approvals. A new oncology CDMO contract was secured, and Fontenay facility expansion will add 30 million ampoule capacity by 2027.

📄 View Original Announcement (PDF)

📊 Stock Analysis — GLAND ✨ Ask AI About This